New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
OverviewChart

Quote Panel

Shape
Updated June 17, 2025
1W % 1M % 3M % 1Y %

Key Metrics

Shape

  • Market Cap

  • Shares Outstanding

  • Share in Float

  • Dividende

  • Earning Date

    No Data

  • Price Target

  • Average Volume

  • Beta

  • Range

  • Industry

  • Website

  • Sector

Fundamentals

Shape

Relative Strength

Shape

MLYS

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

Analyst rating

Last analyst upgrade/downgrade

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.23

arrow
arrow

N/A

-0.31
vs -0.35

Q3.23

arrow
arrow

N/A

-0.57
vs -1288.84

Q4.23

arrow
arrow

N/A

-0.61
vs -1.74

Q1.24

arrow
arrow

N/A

-0.70
vs -0.51

Q2.24

arrow
arrow

N/A

-0.83
vs -0.31

Q3.24

arrow
arrow

N/A

-1.13
vs -0.57

Q4.24

arrow
arrow

N/A

-0.98
vs -0.61

Q1.25

arrow
arrow

N/A

-0.79
vs -0.70

Q2.25

arrow
arrow

N/A

-0.73
vs -0.83

Q3.25

arrow
arrow

N/A

-0.72
vs -1.13

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

NA  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Q3.24

arrow
arrow

NA

NA  vs NA

Q4.24

arrow
arrow

NA

NA  vs NA

Q1.25

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q2.23

arrow
arrow

-4%

-0.04
vs -0.04

Q3.23

arrow
arrow

-9%

-0.09
vs -0.04

Q4.23

arrow
arrow

-10%

-0.10
vs -0.09

Q1.24

arrow
arrow

-10%

-0.10
vs -0.10

Q2.24

arrow
arrow

-14%

-0.14
vs -0.10

Q3.24

arrow
arrow

-24%

-0.24
vs -0.14

Q4.24

arrow
arrow

-26%

-0.26
vs -0.24

Q1.25

arrow
arrow

-12%

-0.12
vs -0.26

Institutionnal OwnershipShape

status-upQoQ

Q1.23

arrow
arrow

66

66
vs NA

NA

Q2.23

arrow
arrow

68

68
vs 66

3%

Q3.23

arrow
arrow

77

77
vs 68

13%

Q4.23

arrow
arrow

88

88
vs 77

14%

Q1.24

arrow
arrow

94

94
vs 88

7%

Q2.24

arrow
arrow

95

95
vs 94

1%

Q4.24

arrow
arrow

107

107
vs NA

NA

Q1.25

arrow
arrow

159

159
vs 107

49%

Earnings Growth

Latest News

MLYS

globenewswire.com

4 hours ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
MLYS

globenewswire.com

7 hours ago

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
MLYS

globenewswire.com

8 hours ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
MLYS

zacks.com

9 hours ago

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
MLYS

zacks.com

13 hours ago

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy
MLYS

seekingalpha.com

20 hours ago

Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript